UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 14A

          Consent Statement Pursuant to Section 14(a) of the Securities
                    and Exchange Act of 1934 (Amendment No. )

Filed by the Registrant [  ]

Filed by a Party other than the Registrant [X]

Check the appropriate box:

[ ]  Preliminary Proxy Statement

[ ]  Confidential, for Use of the Commission Only (as permitted by Rule
     14a-6(e)(2))

[ ]  Definitive Proxy Statement

[X]  Definitive Additional Materials

[ ]  Soliciting Material Pursuant to sec. 240.14a-12


                                 NEOPHARM, INC.
                (Name of Registrant as Specified in its Charter)
                              JOHN N. KAPOOR, Ph.D.
   (Name of Person(s) Filing Consent Statement, if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):

[X]  No fee required.

[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and 0-11

(1)  Title of each class of securities to which transaction applies:

(2)  Aggregate number of securities to which transaction applies:

(3)  Per unit price or other underlying value of transaction computed pursuant
     to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is
     calculated and state how it was determined):

(4)  Proposed maximum aggregate value of transaction:

(5)  Total fee paid:

[ ]  Fee paid previously with preliminary materials.

[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.

(1)  Amount Previously Paid:

(2)  Form, Schedule or Registration Statement No.:

(3)  Filing Party:

(4)  Date Filed:





             KAPOOR ASKS GREG YOUNG, NEOPHARM (NASDAQ:NEOL) CEO, TO
                 SET THE RECORD STRAIGHT ON RESIGNATION QUESTION

LAKE FOREST, IL - October 27, 2004 -John N. Kapoor, Ph.D. today announced that
he sent a letter to Greg Young, CEO of NeoPharm, Inc., asking Greg to set the
record straight on whether he would resign if Dr. Kapoor is successful in his
consent solicitation.

The following is the text of the letter:

                                                                October 27, 2004


Gregory P. Young
c/o NeoPharm, Inc.
150 Field Drive, Suite 195
Lake Forest, IL 60045


Dear Greg,

         A number of NeoPharm stockholders have been reporting to me that you
and others have been suggesting that you will resign as President and CEO of
NeoPharm if I am successful in my consent solicitation. I have to tell you, I
was quite surprised to hear that. Your letter to stockholders certainly did not
indicate any such intention. And, it would seem premature for you to have formed
an apparently negative opinion of me, when you have had very little personal
experience working with me. These reports from stockholders are also surprising
because I have repeatedly said, publicly, that I am not planning on replacing
you. Quite the contrary, I am looking forward to working with you and your
management team to get NeoPharm back on track. If I am successful in my consent
solicitation, I believe we both owe it to each other to give the relationship a
chance.

         Greg, I think that you owe it to the NeoPharm stockholders to be clear
with them about your true intentions. If you have indicated to some NeoPharm
stockholders that you will resign, then why won't you say that publicly for all
NeoPharm stockholders to hear? If your intentions have been misunderstood, then
why not step up and correct the record and tell them that you are committed to
NeoPharm and won't resign simply as a result of the outcome of the consent
solicitation? NeoPharm's stockholders are waiting for an answer.

         Will you give them a straight answer?

                                                    Sincerely,

                                                    /s/ John N. Kapoor, Ph.D.

                                                    John N. Kapoor, Ph.D.



Dr. Kapoor is soliciting consents from NeoPharm to elect three new independent
directors to NeoPharm's board of directors and remove the Other Incumbent
Directors, as well as approve certain other proposals.

For more information about how to execute and deliver your consent, or if you
have any questions or require any assistance, please contact our consent
solicitor, Innisfree M&A Incorporated, toll-free at 1-888-750-5834.


Source:  EJ Financial Enterprises, Inc.
         Michael L. Babich (847) 296-8665 ext. 120